US EditionVCN-01 with chemo boosts survival in metastatic pancreatic cancer
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
VCN-01 with chemo boosts survival in metastatic pancreatic cancer
Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, in a Phase 2b trial. Compared with participants in the VIRAGE trial (NCT05673811) who received chemotherapy alone, those treated with VCN-01 also experienced a longer time without disease progression. “The exc…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
